AnervaX DR4/1 peptide vaccine data

ANRG (Redwood City, Calif.) presented Phase I results in 20 patients showing safety and tolerability of all doses. The vaccine is derived from a part of the HLA antigen associated with arthritis.

Doses tested were 40 to 400 µg, and produced primary humoral response in 25 percent of the patients (antibody titers of 200 to 6400) given a single intramuscular injection. ...